Ronovo Surgical announced today that it closed its Series D financing round with a total investment of $67 million.
Johnson & Johnson’s corporate venture capital organization, JJDC, led the financing. With the Series D closing, Ronovo also signed a targeted collaboration agreement with J&J to advance its surgical robot commercialisation efforts in China. The collaboration offers hospitals in portions of China the advantages of the Carina modular robotic surgery platform, along with complementary J&J MedTech surgical technologies.
Lilly Asia Ventures, INCE Capital and Granite Asia also participated in the round.
Related: Boomerang Medical raises $20M for sacral neuromod tech for inflammatory bowel disease
Shanghai-based Ronovo adds the $67 million to a Series C raised earlier this year, bringing its total funding to more than $100 million in 2025. On top of that $100 million, the company also brought in a $46 million Series B last year.
Ronovo unveiled the Carina platform in February 2023 as a modular system built on proprietary technology to enable configurable robotic assistance for laparoscopic surgeries across multiple specialties.
Carina addresses numerous pain points in minimally invasive surgeries. The company says it provides surgeons with the flexibility to choose the best instruments and the most ideal anatomical access. The system received approval from China’s National Medical Products Administration (NMPA) in March 2025. This made it the first modular surgical robotic system in the country to obtain a first-time filing covering four major specialties (general surgery, gynecology, urology and thoracic surgery), according to Ronovo.
In parallel with the funding, Ronovo said it initiated global expansion efforts. It currently has submissions underway in Europe and South America.
“We are grateful for the successful closing of our Series D round led by JJDC,” said Dr. John Ma, Ronovo’s founder, chair and CEO. “Carina — flexible, adaptable and affordable — embodies our commitment to democratizing access to surgical robotics on a global scale. We’re excited about the strategic collaboration with Johnson & Johnson MedTech, which will further accelerate our commercial momentum in China while laying the foundation for international growth.”
